Henry Schein Inc HSIC

Zacks Investment Research 5 nov

Henry Schein (HSIC) has been identified as an attractive growth stock by Zacks' proprietary system, earning a Zacks Rank #2 (Buy) and Growth Score of B. The company demonstrates strong fundamentals including projected EPS growth of 10.6% (vs. industry average of 5.3%), efficient asset utilization with an S/TA ratio of 1.21 (vs. industry average of 0.77), and positive earnings estimate revisions with current-year estimates up 3.5% over the past month. Sales are expected to grow 5% this year compared to the industry average of 2.6%.

Zacks Investment Research 5 nov

Henry Schein (HSIC) has been upgraded to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 remains at $5.50 per share, with analysts raising estimates by 3.6% over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation driven by improving business fundamentals.

Zacks Investment Research 5 nov

In a comparison of two medical-dental supplies stocks, Henry Schein (HSIC) emerges as the better value opportunity compared to Merit Medical (MMSI). HSIC holds a Zacks Rank #2 (Buy) with a Value grade of A, featuring a lower forward P/E ratio of 16.05 and a PEG ratio of 1.56. MMSI, ranked #3 (Hold) with a Value grade of C, has a higher forward P/E of 21.06 and PEG ratio of 1.98, making HSIC more attractive to value investors.

Zacks Investment Research 3 nov

Henry Schein reported Q3 2026 earnings of $1.56 per share, beating consensus estimates of $1.34 by 16.42%, with revenues of $3.47 billion meeting expectations. The stock has outperformed the S&P 500 by 4.4% year-to-date. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions. Becton Dickinson is expected to report results on November 5 with projected earnings of $4.06 per share, though revenues are expected to decline 13% year-over-year.

Zacks Investment Research 30 oct

Henry Schein (HSIC), a healthcare solutions company, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and an A VGM Score. The stock has shown positive momentum with a 1.8% gain over the past four weeks and an average earnings surprise of +6.5%, making it noteworthy for momentum investors despite its Hold rating.